Literature DB >> 33488965

Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR·uPA Interaction.

Khuchtumur Bum-Erdene1, Degang Liu1, David Xu2, Mona K Ghozayel1, Samy O Meroueh1.   

Abstract

There is substantial interest in the development of small molecules that inhibit the tight and highly challenging protein-protein interaction between the glycophosphatidylinositol (GPI)-anchored cell surface receptor uPAR and the serine protease uPA. While preparing derivatives of a fragment-like compound that previously emerged from a computational screen, we identified compound 5 (IPR-3242), which inhibited binding of uPA to uPAR with submicromolar IC50s. The high inhibition potency prompted us to carry out studies to rule out potential aggregation, lack of stability, reactivity, and nonspecific inhibition. We designed and prepared 16 derivatives to further explore the role of each substituent. Interestingly, the compounds only partially inhibited binding of a fluorescently labeled α-helical peptide that binds to uPAR at the uPAR·uPA interface. Collectively, the results suggest that the compounds bind to uPAR outside of the uPAR·uPA interface, trapping the receptor into a conformation that is not able to bind to uPA. Additional studies will have to be carried out to determine whether this unique inhibition mechanism can occur at the cell surface.
© 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 33488965      PMCID: PMC7812671          DOI: 10.1021/acsmedchemlett.0c00422

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

1.  Structure of human urokinase plasminogen activator in complex with its receptor.

Authors:  Qing Huai; Andrew P Mazar; Alice Kuo; Graham C Parry; David E Shaw; Jennifer Callahan; Yongdong Li; Cai Yuan; Chuanbing Bian; Liqing Chen; Bruce Furie; Barbara C Furie; Douglas B Cines; Mingdong Huang
Journal:  Science       Date:  2006-02-03       Impact factor: 47.728

2.  Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.

Authors:  Qing Huai; Aiwu Zhou; Lin Lin; Andrew P Mazar; Graham C Parry; Jennifer Callahan; David E Shaw; Bruce Furie; Barbara C Furie; Mingdong Huang
Journal:  Nat Struct Mol Biol       Date:  2008-03-23       Impact factor: 15.369

3.  Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.

Authors:  Timmy Mani; Fang Wang; William Eric Knabe; Anthony L Sinn; May Khanna; Inha Jo; George E Sandusky; George W Sledge; David R Jones; Rajesh Khanna; Karen E Pollok; Samy O Meroueh
Journal:  Bioorg Med Chem       Date:  2013-01-09       Impact factor: 3.641

4.  Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.

Authors:  Timmy Mani; Degang Liu; Donghui Zhou; Liwei Li; William Eric Knabe; Fang Wang; Kyungsoo Oh; Samy O Meroueh
Journal:  ChemMedChem       Date:  2013-10-02       Impact factor: 3.466

5.  A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.

Authors:  Y Guo; A A Higazi; A Arakelian; B S Sachais; D Cines; R H Goldfarb; T R Jones; H Kwaan; A P Mazar; S A Rabbani
Journal:  FASEB J       Date:  2000-07       Impact factor: 5.191

6.  Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.

Authors:  Y Wei; J A Eble; Z Wang; J A Kreidberg; H A Chapman
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

7.  Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking.

Authors:  Henrik Gårdsvoll; Bernard Gilquin; Marie Hélène Le Du; Andre Ménèz; Thomas J D Jørgensen; Michael Ploug
Journal:  J Biol Chem       Date:  2006-05-03       Impact factor: 5.157

8.  Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.

Authors:  D M Ignar; J L Andrews; S M Witherspoon; J D Leray; W C Clay; K Kilpatrick; J Onori; T Kost; D L Emerson
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 5.150

9.  A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial.

Authors:  Anna Berkenblit; Ursula A Matulonis; Joan F Kroener; Bruce J Dezube; Gil N Lam; Luceli C Cuasay; Nils Brünner; Terence R Jones; Michael H Silverman; Michael A Gold
Journal:  Gynecol Oncol       Date:  2005-10       Impact factor: 5.482

10.  Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists.

Authors:  David Xu; Khuchtumur Bum-Erdene; Yubing Si; Donghui Zhou; Mona K Ghozayel; Samy O Meroueh
Journal:  ChemMedChem       Date:  2017-10-23       Impact factor: 3.466

View more
  2 in total

Review 1.  Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.

Authors:  Nehad S El Salamouni; Benjamin J Buckley; Marie Ranson; Michael J Kelso; Haibo Yu
Journal:  Biophys Rev       Date:  2022-01-06

Review 2.  Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer.

Authors:  Maria Teresa Masucci; Michele Minopoli; Gioconda Di Carluccio; Maria Letizia Motti; Maria Vincenza Carriero
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.